Status: Recruiting
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
Participants needed: 96
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaUpdated: Aug 17, 2022Locations: 1
Eligibility criteria
Lung adenocarcinoma patient with EGFR sensitive mutation as confirmed by needle... [+9]
The patient has undergone any systemic anti-cancer treatment for NSCLC, includin... [+8]